After sensitivity analysis, there was no significant difference in decreasing the number of HBsAg positive newborns (RR: 1.69, 95% CI [0.66, 4.31], P?=?.27) with no heterogeneity (P?=?.91, I2?=?0%). meta-analysis. Compared with placebo group, HBIG and HBVac group experienced a significant decrease in the number of newborns who were HBsAg positive (relative risks [RR]: 0.2, 95% confidence interval [CI] [0.18, 0.40], P?.00001) and HBV-DNA positive (RR: 0.25, 95% CI [0.09, 0.71], P?=?.010), and had a significant increase in the number of anti-HBs positive newborns (RR: 3.95, 95% CI [3.11, 5.00], P?.00001). After 1-12 months follow up, the number of HBsAg positive newborns continued to decline (RR: 0.09, 95% CI [0.04, 0.20], P?.00001) and the number of anti-HBs positive newborns continued to increase in HBIG and HBVac group (RR: 1.30, 95% CI [1.22, 1.38], P?.00001). Compared with HBIG group, HBIG and HBVac group experienced no significant difference in the number of HBsAg positive newborns (RR: 1.68, 95% CI [0.66, 4.30], P?=?.28), and had a significant decrease in the number of HBsAg positive newborns (RR: 0.31, 95% CI [0.12, 0.84], P?=?.02). Additionally, only 1 1 study reported 2 swelling cases, 4 studies were reported no adverse events, and 11 studies were not statement adverse reaction. Conclusions: HBIG and HBVac could be an effective alternate for HBsAg positive pregnant women Elaidic acid to prevent mother to child transmission. However, due to the limitations of the study, the long-term efficacy and security of HBIG and HBVac still need long-term and high-quality research to confirm. Keywords: hepatitis B computer virus, immunoprophylaxis, meta-analysis, mother to child Elaidic acid transmission, systematic review 1.?Introduction Chronic hepatitis B (CHB) is a major global health problem, resulting in substantial morbidity and 600,000 deaths per year.[1] Worldwide, it is estimated that 2 billion people have evidence of past or present contamination with hepatitis B computer virus (HBV) and around 650,000 people die of CHB each year from your CHB.[1] As estimated 240 million of 2 billion individuals are chronic carriers of HBV surface antigen (HBsAg) all over the world.[2] Chronic carrier status represents a status of increased risk for chronic hepatitis, liver cirrhosis, and hepatic carcinoma.[3] Mother to child transmission (MTCT) is the main way of HBV transmission in many countries of the world, especially in China and South-East Asia, which may occur during gestation period, perinatal period, or after birth.[2,4] When the mother is infected during the first trimester, 10% neonates may occur HBV MTCT.[5] When the mother is infected during the third trimester, 60% to 90% neonates may occur acute infection.[5] If acute infection is acquired in the last trimester, preterm birth rate may increase. Furthermore, >60% pregnant women acquiring acute hepatitis B contamination will transmit HBV Elaidic acid to their children.[6] Therefore, post exposure prophylaxis is recommended for neonates from all HBsAg positive mothers, regardless of the HBeAg or HBeAb status.[7] HBeAg indicates the infectiousness, the higher concentration of HBeAg and the higher degree of infectiousness.[8] It has been shown hepatitis B immune globulin (HBIG) and hepatitis B vaccine (HBVac) is an effective treatment method for neonates at birth to prevent MTCT of HBV. Although administration of HBIG and HBVac in neonates has significantly reduced HBV carrier rates, however, approximately 1% to 9% of vertical transmissions of HBV were not eliminated by these interventions.[4] Abou et al[9] have showed antenatal period might be a main access point for the antenatal populace to benefit from HBIG in limited resource settings. Eke et al[10] have carried out a systematic review suggesting that HBIG might gain benefits when utilized for prevention of HBV MTCT and prevent neonates from developing HBV infection. Antenatal prevalence of HBsAg determines recommendation for pregnancy vaccination.[11] Some studies have recommended that Elaidic acid Rabbit Polyclonal to SFRS17A administration of HBIG and HBVac to mother might prevent intrauterine infection during pregnancy, although there were some controversies for its efficacy.[10] Therefore, this study aims to evaluate the benefits and harms of HBIG and HBVac in preventing of Elaidic acid HBV MTCT in HBsAg positive pregnant women. Although antiviral medications also have a role in the prevention of HBV MTCT, it is beyond the scope of this review. 2.?Methods 2.1. Literature search Our research comprises of 3 English electronic databases (PubMed, EMBase, and Cochrane Library) and 4 Chinese electronic databases (WanFang Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure,.